13585831301
021-59541103 021-60443211
3004967995
13585831301021-59541103 021-604432113004967995
在線訂購 免費訂購熱線：021-59541103 021-60443211
聯(lián)系人:高小姐
電話:021-59541103 021-60443211
手機:13585831301
Q Q： 3004967995
Email:3004967995@qq.com
詳細地址：上海嘉定區(qū)嘉羅公路1661
化學性質：
| 規(guī)格 | 5mg 25mg 100mg |
| CAS | 915769-50-5 |
| 別名 |
|
| 化學名 | 4-amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxypropanoate hydra |
| 分子式 | C24H29FN6O5 |
| 分子量 | 500.52 |
| 溶解度 | ≥ 168.2mg/mL in H2O |
| 儲存條件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice |
產品描述：
Description:
IC50: ~10 nmol/L for FGFR1–3
Fibroblast growth factor receptor 1 (FGFR1) and FGFR2 amplifications are observed in approximately 10% of breast cancers and are related to poor outcomes. Dovitinib (TKI258) is an oral tyrosine kinase inhibitor (TKI) against FGFR1–3, VEGFR1–3, and platelet-derived growth factor receptor (PDGFR).
In vitro: Dovitinib decreased the concentrations of pFRS2 and pERK/MAPK in a dose-dependent manner in FGFR1 amplified and FGFR2 amplified cell lines. The IC50 for cell growth inhibition was 190 and 180 nmol/L in MDA-MB-134 and SUM52, respectively. Conversely, IC50 values were more than 2,000 nmol/L in the 11 breast cancer cell lines that had neither FGFR1 nor FGFR2 amplification [1].
In vivo: In vivo model (HBCx-2 breast cancer primary xenograft, with 8 FGFR1 gene copies), dovitinib prevented tumor growth at the 30 mg/kg dose and caused tumor regression at the 50 mg/kg dose. Similarly, dovitinib caused tumor regression in HBCx-3 xenografts when administered at a dose of 40 mg/kg daily until day 35 [1].
Clinical trial: Eighty-one patients were enrolled in the trial. Unconfirmed response or stable disease for over 6 months was observed in 5 and 1 patient(s) with FGFR1-amplified/HR-positive and FGFR1-nonamplified/HR-positive breast cancer. When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway–amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients that did not present with FGF pathway–amplified breast cancer [1].
特別提醒：
1. 本產品僅供科研使用。請勿用于醫(yī)藥、臨床診斷或治療，食品及化妝品等用途。請勿存放于普通住宅區(qū)。
2. 為了您的安全和健康，請穿好實驗服并佩戴一次性手套和口罩操作。
原創(chuàng)作者：上海莼試生物技術有限公司
留言注意事項：
1.遵守中華人民共和國有關法律、法規(guī)，尊重網上道德，承擔一切因您的行為而直接或間接引起的法律責任。
2.請您真實的反映產品的情況,不要捏造、誣蔑、造謠。如對產品有任何疑問,也可以留言咨詢。
3.未經本站同意，任何人不得利用本留言簿發(fā)布個人或團體的具有廣告性質的信息或類似言論。
| 您感興趣的產品* | |
| 您的單位* | |
| 聯(lián)系人* | |
| 聯(lián)系電話* | |
| 詳細地址* | |
| 常用郵箱* | |
| 請輸入您對我們的意見或建議* | |
| 驗證碼* | |
 |
產品訂購說明:
1、報價含普票、運費。
2、常用試劑備貨充足，除對溫度要求極其嚴格的產品當天可發(fā)貨。
3、進口原裝產品要3-6周的貨期，詳細情況請咨詢客服。
4、訂貨時間為工作日每周一至周五16:00之前。
5、如需代為檢測，標本對環(huán)境溫度高，可聯(lián)系客服安排專人取樣（限省內客戶）。
6、代測免收代測費，一周出結果。
7、產品因運輸途中包裝破損請拒絕簽收，做退回。我們將在24小時之內為您補發(fā) 損壞產品。
8、如因單位財務制度原因，可申請先發(fā)貨，報賬后付款（此條款僅限醫(yī)院、學校信譽良好客戶）。
普票匯款信息
賬 戶 名：上海生物
開 戶 行：中國銀行山東省分行營業(yè)部
賬 號：2169 2341 6278
關于莼試
產品訂購
新手指南
幫助中心